ADORA2A and hepatocellular carcinoma: To further explore whether PI3K/AKT pathway is also the critical mediator of the roles of ADORA2A-AS1 in HCC, SNU-398 cells with ADORA2A-AS1 stable silencing were treated with PI3K/AKT pathway inhibitor LY294002.